Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M002362200 on May 11, 2000

J. Biol. Chem., Vol. 275, Issue 33, 25608-25615, August 18, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/33/25608    most recent
M002362200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michalet, S.
Right arrow Articles by Kessler, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michalet, S.
Right arrow Articles by Kessler, P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Relative Spatial Position of a Snake Neurotoxin and the Reduced Disulfide Bond alpha (Cys192-Cys193) at the alpha gamma Interface of the Nicotinic Acetylcholine Receptor*

Sophie MichaletDagger §, Fatima TeixeiraDagger , Bernard GilquinDagger , Gilles MourierDagger , Denis ServentDagger , Pascal DrevetDagger , Patrice Binder||, Socrates Tzartos**, André MénezDagger , and Pascal KesslerDagger DaggerDagger

From the Dagger  CEA/Saclay, Département d'Ingénierie et d'Etudes des Protéines, 91191 Gif-sur-Yvette, France, || DGA/DSP-STTC, 26 Bd Victor, 00460 Armées, France, and the ** Hellenic Pasteur Institute, 127 Vassilisis Sofias Avenue, 11521 Athens, Greece

Received for publication, March 20, 2000, and in revised form, May 8, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We determined the distances separating five functionally important residues (Gln10, Lys27, Trp29, Arg33, and Lys47) of a three-fingered snake neurotoxin from the reduced disulfide bond alpha (Cys192-Cys193) located at the alpha gamma interface of the Torpedo nicotinic acetylcholine receptor. Each toxin position was substituted individually for a cysteine, which was then linked to a maleimido moiety through three different spacers, varying in length from 10 to 22 Å. We estimated the coupling efficiency between the 15 toxin derivatives and the reduced cystine alpha (192-193) by gel densitometry of Coomassie Blue-stained gels. A nearly quantitative coupling was observed between alpha Cys192 and/or alpha Cys193 and all probes introduced at the tip of the first (position 10) and second (position 33) loops of Naja nigricollis alpha -neurotoxin. These data sufficed to locate the reactive thiolate in a "croissant-shaped" volume comprised between the first two loops of the toxin. The volume was further restrained by taking into account the absence or partial coupling of the other derivatives. Altogether, the data suggest that alpha Cys192 and/or alpha Cys193, at the alpha gamma interface of a muscular-type acetylcholine receptor, is (are) located in a volume located between 11.5 and 15.5 Å from the alpha -carbons at positions 10 and 33 of the toxin, under the tip of the toxin first loop and close to the second one.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The nicotinic acetylcholine receptor (nAChR)1 is a transmembrane protein, composed of five subunits (alpha 2beta gamma delta for the muscular type), which represents the prototype of the ligand-gated ion channels. It is quasi-irreversibly blocked by snake curarimimetic toxins, a feature which helped in the isolation and purification of the receptor almost three decades ago. However, only recently has some light been shed on the molecular interaction between snake toxins and the nAChR. At least 10 residues of a sea snake toxin are involved in binding to the receptor from Torpedo marmorata, i.e. Gln7, Ser8, Gln10, Lys27, Trp29, Asp31, Arg33, Ile36, Glu38, and Lys47 (1, 2). Receptor regions that interact with snake toxins have also been investigated in various studies. Some lines of evidence indicate that snake toxins can bind to two sites located at the interfaces of the alpha gamma - and alpha delta -subunits (3-5). Among the different receptor regions that may be implicated in toxin binding, the domain 180-200 of the alpha -subunit is clearly an important determinant (for a review see Ref. 6). It is also involved in various other binding functions, because it is recognized by small organic agonists (7) and small antagonists (8-12). More recently, double mutant cycle analyses have revealed a number of contacts that may occur between nAChR and a cobra curarimimetic toxin (13-15). Thus, Arg33 of NmmI toxin is coupled to the receptors alpha Val188 and gamma Leu119, whereas the toxin Lys27 interacts with gamma Glu176, and to a lesser extent with alpha Tyr190, Pro197, and Asp200. Although double mutant cycle analyses have evaluated the distances between various charged residues of this short-chain toxin and some residues of the receptor gamma -subunit (15), the relative positioning of the toxin with respect to the receptor alpha -subunit still remains unclear. To address this question, we have estimated the distances that separate several functionally important toxin residues from Cys192 and/or Cys193, two residues that belong to the critical binding region 180-200 of the two alpha -subunits. More precisely, we used experimental conditions that allowed us to perform this study at a single binding site, namely, the site at the alpha gamma interface.

It is known that the disulfide bond alpha (Cys192-Cys193) can be selectively reduced without affecting antagonist binding (16) and hence specifically labeled with irreversible antagonists (8, 17, 18) or agonists (19). Treatment of the receptor with bromoacetylcholine or [4-(N-maleimido)benzyl]trimethylammonium iodide (MBTA) in the presence of a disulfide reducing agent leads to the covalent modification of one or both alpha -subunits, depending on the concentration of affinity label (20-22). Even more interestingly perhaps, when the reducing agent is eliminated before the alkylation step, only one site is labeled by both probes, independent of their concentrations (22). This site has been demonstrated to correspond to the high affinity binding site of d-tubocurarine (23), which was later located at the alpha gamma interface of the receptor (11, 24). Using radioactive MBTA, it was further demonstrated that alpha Cys192 and alpha Cys193 are the exclusively labeled residues (8).

Our strategy was inspired from this site-directed alkylation procedure. First, we chemically engineered analogues of a curarimimetic snake toxin, by automated peptide synthesis. More precisely, we individually replaced each of the five functional residues Gln10, Lys27, Trp29, Arg33, and Lys47 by a cysteine residue. The reason for the choice of these residues was that they are both important binding contributors to toxin-receptor formation and are widely spread over the functional topography of the snake toxin (1, 2). Second, we linked each of them to three spacers of different lengths (10, 14, and 22 Å) that always ended in a maleimido group. Third, each of the 15 monomodified toxin derivatives was mixed with the receptor whose alpha (Cys192-Cys193) disulfide bond was selectively reduced and affinity-labeled under conditions where only the alpha gamma interface was modified (23). Fourth, the coupling yield was estimated from gel electrophoresis experiments. Fifth, the data were exploited to build a model in which the toxin was positioned relative to cysteines 192 and/or 193 of the alpha -subunit at the alpha gamma interface.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Peptides were synthesized with an Applied Biosystems 433 apparatus, using Fmoc-protected amino acids of the highest purity commercially available from Novabiochem or Advanced Chemtech. N,N'-(1,2-phenylene)dimaleimide and N,N'-(1,4-phenylene)dimaleimide were from Aldrich, and N,N'-bis(3-maleimidopropionyl)-2-hydroxy-1,3-propanediamine was from Sigma. [alpha -125I]bungarotoxin (Bgtx) (200 Ci.mmol-1) was from Amersham Pharmacia Biotech. Live T. marmorata were from the Station Biologique d'Arcachon (France). Naja nigricollis horse antivenom serum was from the Institut Pasteur (France). Goat anti-rat (GAR-PO) and rabbit anti-horse (RAH-PO) IgG peroxidase conjugates were from Jackson ImmunoResearch Laboratories (West Grove, PA). Electrospray mass spectrometry was carried out using a Quattro II spectrometer from Micromass. Circular dichroism spectra were recorded on a Jobin Yvon CD6 dichrograph at 22 °C.

HPLC Conditions-- Reverse-phase high performance liquid chromatography (HPLC) purifications were done with a Vydac C4 semipreparative column (10 × 250 mm; flow rate, 4 ml.min-1; linear gradient, 5% to 21% B in 6 min; then 21% to 27% B in 19 min (A, H2O -0.1% trifluoroacetic acid; B, CH3CN -0.06% trifluoroacetic acid)).

Membrane Preparations-- nAChR-rich membranes from the electric tissue of T. marmorata were prepared, as described previously (25), in the presence of 20 mM N-ethylmaleimide to block all free cysteines. They were further purified by alkali treatment (26). The concentration of acetylcholine binding sites was measured at equilibrium with [alpha -125I]Bgtx (27).

Synthesis of Toxin Analogues-- N. nigricollis alpha -toxin analogues were synthesized as described earlier (28-30) and refolded with 1.5-15 mM oxidized dithiothreitol (DTT) overnight, under inert atmosphere. The refolded toxins were purified by reverse-phase HPLC as described above, and checked by electrospray mass spectrometry and circular dichroism.

To conjugate the single free cysteine (Q10C, K27C, W29C, R33C, or K47C) of each toxin mutant with dimaleimide reagents, we first solubilized 0.7 mg (0.1 µmol) of toxin analogue in 200 µl of 250 mM sodium acetate buffer (pH 5.5)/2.5 mM EDTA and 100 µl of H2O. The solution was then poured on 20 equivalents of dimaleimide-containing reagent dissolved in either a mixture of dimethylformamide (40 µl)/acetone (160 µl) for the two shorter reagents (Mal10 and Mal14) or in 200 µl of sodium acetate buffer for the longest (Mal22) reagent, with rapid stirring. The mixture was left at room temperature for 30 min, except for the K27C derivatives, where the incubation time was prolonged to 8 h. Excess reactant was removed by exclusion chromatography (Biogel P2 from Bio-Rad), with the toxin migrating in the void volume. Each maleimido-toxin derivative was purified by HPLC as described above, and its mass was determined by electrospray mass spectrometry.

Binding Assays-- Binding competition experiments were performed at equilibrium, using [alpha -125I]Bgtx (200 Ci.mmol-1) as radioactive tracer. Varying amounts of toxins were incubated in Ringer's buffer (5 mM sodium phosphate buffer, pH 7, 250 mM NaCl, 5 mM KCl, 4 mM CaCl2, 2 mM MgCl2, 0.02% NaN3, 0.01% Triton X-100), with 0.3 nM alpha -toxin binding sites and 9 nM [alpha -125I]Bgtx for 5 h at room temperature. The mixture was filtered through Millipore filters (HAWP), which had been soaked in the same buffer. The filters were rinsed twice with 5 ml of Ringer's buffer and counted on a 1261-multigamma counter (Amersham Pharmacia Biotech). Equilibrium dissociation constants were determined from IC50 values according to Cheng and Prusoff (31).

Reduction of alpha (Cys192-Cys193)-- Selective reduction of the alpha (Cys192-Cys193) bond was carried out using a slight modification of a previously described procedure (22). Briefly, the nAChR (3.3 nmol of toxin binding sites) was incubated under argon in degassed sodium phosphate buffer (100 mM, pH 7.6, 2.5 mM EDTA) containing 1 mM DTT, for 20 min at room temperature. The sample was centrifuged at 17,600 × g for 15 min at 4 °C. The supernatant was removed, and the pellet was resuspended in 600 µl of degassed buffer A (250 mM sodium phosphate, pH 6.9, 2.5 mM EDTA) under argon. The last step was reproduced twice to eliminate excess DTT, and the pellet was resuspended in 1.1 ml of the same buffer, under argon.

Affinity Labeling-- For affinity-labeling experiments, the reduced nAChR (1 µM toxin binding sites) was mixed with each purified maleimido-toxin derivative (1 µM final concentration) in buffer A (200-µl final volume). After 15- or 90-min incubation at room temperature, under argon, each sample was centrifuged as described above. The supernatant was removed, and the pellets were resuspended in 70 µl of Laemmli buffer.

For protection experiments, the reduced receptor was first incubated with native erabutoxin a (70 µM) for 2 h at room temperature, under argon, before reaction with the maleimido derivatives.

Protection with Bromoacetylcholine-- After reduction, the receptor was incubated with 10 µM bromoacetylcholine for 10 min at room temperature, under argon, in the presence of 5 µM tacrine (inhibition of acetylcholinesterase). The receptor was then reacted as described above with R33C-Mal22 for 15 min.

SDS-PAGE and Immunoblots-- SDS-polyacrylamide gel electrophoresis (PAGE) was performed according to Laemmli (32) using a mini-protean apparatus (Bio-Rad). Briefly, about 30 µg of each sample was electrophoresed on a 10% SDS gel of 1-mm thickness, which was then stained with Coomassie Blue. For immunoblots, 3- to 10-µg protein samples were subjected to SDS-PAGE and then transferred to a polyvinylidene fluoride (PVDF) microporous membrane. The PVDF sheet was quenched for 2 h at room temperature with buffer B (10 mM sodium phosphate, pH 7.4, 150 mM NaCl) containing 2% bovine serum albumin. The sheet was incubated overnight at 4 °C with monoclonal antibody 155 (33) (1/4000), or horse antiserum to the venom (1 mg.ml-1) solubilized in 10 ml of quench buffer. The PVDF membrane was washed (four times for 5 min) in buffer B containing 0.1% Triton X-100. Peroxidase-labeled antibodies GAR-PO or GAH-PO (1/4000) in 10 ml of quench buffer was added to the PVDF membrane for 1 h at room temperature. The PVDF sheet was washed again (four times for 5 min) in phosphate buffer containing 0.1% Triton X-100 and for 5 more min in the same buffer without Triton. The solution containing the peroxidase substrate was used when freshly prepared and consisted of 25 ml of phosphate buffer, 250 µl of CoCl2 solution (30 g.l-1), and 25 µl of H2O2 solution (30%). Development was stopped by rinsing the membrane in water.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Preparation and Characterization of Cysteine-containing Toxin Derivatives-- Toxin alpha  from N. nigricollis is amenable to peptide synthesis on the micromole scale by automated Fmoc solid-phase peptide synthesis (28-30). We thus prepared five toxin derivatives in which the functionally important Gln10, Lys27, Trp29, Arg33, and Lys47 (1, 2) (Fig. 1) were individually replaced by a cysteine. The deprotected peptides were then reoxidized in the presence of oxidized DTT. The resulting proteins all had a wild-type toxin secondary structure, as indicated by the similarity of their CD spectra (Fig. 2). The unique exception was the W29C derivative, which displayed no positive peak at 230 nm, a finding that confirms that this band is associated with a contribution of the tryptophan residue (34). Each protein possesses a single cysteine, as assessed with Ellman's reagent (35), and is characterized by the expected mass determined by electrospray mass spectrometry (not shown). Up to 15 mg of each toxin derivative was obtained, the overall average yield of synthesis being about 5%. Therefore, none of the substitutions of any of the five original functional residues by a cysteine altered the capacity of the toxin to refold with its native-like secondary structure.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 1.   N. nigricollis alpha -neurotoxin. The structure has been taken from Zinn-Justin et al. (51). The five residues, which were individually replaced by a cysteine, are shown in boldface font.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 2.   Circular dichroism spectra of the five "cysteine" analogues of N. nigricollis alpha -neurotoxin derivatives. The polypeptides were dissolved in water at 50 µM final concentration. The cell path length was 0.2 cm. (---) native toxin, (- - -) Q10C, (- - -) K27C, (...) W29C, (- · - · -) R33C, and (--- · · · ---) K47C.

As expected for residues that are critical for toxin binding to nAChR, their replacement by cysteine caused binding affinity decreases (Table I). The wild-type toxin had a Ki of 13 pM, consistent with its Kd value (36), and this value decreased 4-, 18-, 145-, 12-, and 29-fold upon use with mutations Q10C, K27C, W29C, R33C, and K47C, respectively. Despite the affinity decreases, the analogues still retained relatively high binding affinities.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Inhibition constants of N. nigricollis derivatives for T. marmorata nAChR
Inhibition constants were obtained by competition at equilibrium against alpha -[125I]bungarotoxin (9 nM) on T. marmorata nAChR (0.3 nM toxin binding sites). Values were estimated according to Cheng and Prusoff (31). Mean ± S.E. or standard errors for two or more measurements.

Introduction of Maleimide-containing Reagents into Cysteine-containing Toxins-- Three dimaleimides called Mal10, Mal14, and Mal22 (Fig. 3) were reacted with the additional cysteine introduced into each of the five toxin mutants. To avoid formation of toxin dimers and to favor formation of monomodified derivatives, we used a large excess of dimaleimides (20 eq). Excess reactant was subsequently eliminated by gel exclusion, and the 15 derivatives were purified by reverse-phase HPLC. All but the K47C-Mal10 derivative eluted as a single peak, which is strongly indicative of their homogeneity. The K47C-Mal10 derivative HPLC profile showed a slight but unexplained shoulder (not shown). All the derivatives displayed the expected mass (not shown) and were used as such for the labeling experiments.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   Products obtained by coupling the free cysteinyl residue of each toxin analogue with three different dimaleimides in excess. One maleimide moiety has reacted with the introduced thiol on the toxin, leading to a stable succinimidyl bond. The second maleimide moiety is left for reaction with the reduced receptor. The given distances correspond to the maximal length between the cysteine alpha -carbon and the reactive carbon on the maleimide moiety.

All chemically modified derivatives but W29C displayed similar affinities for nAChR as compared with cysteine-containing derivatives (Table I). Due to a lack of material, we could not determine the IC50 values for W29C maleimido analogues. Interestingly, the K27C-Mal22 derivative discriminated between the two toxin binding sites, one of them being recognized with almost the same affinity as for the wild-type toxin and the other with an affinity approximately two orders of magnitude lower.

Affinity Labeling of the Reduced Receptor-- At first, all free cysteines of a membrane preparation of nAChR were blocked using 20 mM N-ethylmaleimide. The nAChR possesses three types of disulfide bonds spread over the extracellular domains of the various subunits. These are Cys128-Cys142 on all subunits, Cys192-Cys193 on the two alpha -subunits, and the Cys500-Cys500 on the delta -subunits, linking two monomers of the receptor (37, 38). Under mild reducing conditions, only the alpha (Cys192-Cys193) disulfide bond is affinity-labeled (8), and if the reducing agent is eliminated before the alkylation step, only the alpha gamma interface is labeled (23). We therefore carefully considered this procedure in a tentative attempt to generate selective labeling of the reduced alpha (Cys192-Cys193) bond at the alpha gamma interface.

Incubation of the 15 maleimido-containing derivatives with the reduced nAChR was analyzed by SDS-PAGE and revealed by Coomassie Blue staining (Fig. 4A). The control lane with no derivative (lane 1) shows the four expected nAChR subunits. Clear changes in intensity patterns were only seen for all derivatives modified at Q10C and R33C and for the derivative W29C-Mal22 (Fig. 4A; lanes 2, 3, 4, 10, 11, 12, and 13). In all these cases, the intensity of the alpha -subunit decreased. This change was concomitantly associated with an increased intensity in the beta -subunit, whose apparent molecular mass was close to 46 kDa, which not only fits with the beta -subunit but also with a complex consisting of an alpha -subunit molecule associated with one toxin molecule. No such clear-cut phenomenon was seen with the eight other derivatives. Neither was it seen in control experiments where the receptor was not reduced, nor when the reduced receptor was treated with the well-known thiol blocking reagents N-ethylmaleimide or 5,5'-dithiobis-(2-nitrobenzoic acid) (not shown). Moreover, when the reduced nAChR was pretreated with an excess of an analogous snake toxin, erabutoxin a, the effect vanished for all the derivatives, except for the Q10C analogues for which the protection from affinity labeling was around 80% (data not shown). These data indicate that the phenomenon (i) is associated with the presence of free cysteines 192 and 193, (ii) requires a maleimido-containing toxin derivative, and (iii) is specific to the introduced linkers located at positions 10, 29, and 33. 


View larger version (77K):
[in this window]
[in a new window]
 
Fig. 4.   Visualization of the labeling of the alpha -subunit of T. marmorata nAChR. The receptor was reduced for 20 min with 1 mM DTT, at room temperature, under argon atmosphere, in phosphate buffer (100 mM, pH 7.6, 2.5 mM EDTA). After three steps of centrifugation (see "Experimental Procedures"), the reduced receptor (1 µM toxin binding sites) was incubated with the 15 toxin analogues (1 µM) for 15 min at room temperature, under argon atmosphere. A, Coomassie Blue staining of an SDS-PAGE gel of the reduced nAChR after coupling with the 15 toxin derivatives. 10Å, 14Å, and 22Å represent the Mal10, Mal14, and Mal22 linkers, respectively, on each cysteine analogue. Reduced Torpedo membrane fragments (lane 1); same fragments after coupling with Q10C-Mal10 (lane 2), Q10C-Mal14 (lane 3), Q10C-Mal22 (lane 4), K27C-Mal10 (lane 5), K27C-Mal14 (lane 6), K27C-Mal22 (lane 7), W29C-Mal10 (lane 8), W29C-Mal14 (lane 9), W29C-Mal22 (lane 10), R33C-Mal10 (lane 11), R33C-Mal14 (lane 12), R33C-Mal22 (lane 13), K47C-Mal10 (lane 14), K47C-Mal14 (lane 15), and K47C-Mal22 (lane 16). Molecular weight markers (lane 17). B, immunoblot with a horse serum directed against N. nigricollis venom. The lanes correspond to the same derivatives as in A. C, immunoblot with monoclonal antibody 155, a monoclonal antibody directed against the nAChR alpha -subunit. The lanes correspond to the same derivatives as in A. D, inhibition of labeling by R33C-Mal22 with 10 µM bromoacetylcholine (BAC): reduced nAChR labeled with R33C-Mal22 (lane a), reduced nAChR labeled with 10 µM BAC (lane b), and reduced nAChR labeled with 10 µM BAC before reaction with R33C-Mal22 (lane c).

To demonstrate that the toxin moiety was covalently associated with the new 46-kDa protein band, we blotted an SDS gel previously incubated with antitoxin antibodies present in a snake antivenom (Fig. 4B). Curiously, nonspecific detection was seen weakly at the level of the alpha -subunit and even more weakly around the beta -subunit (Fig. 4B, lane 1). Nevertheless, strong differential labeling was readily observed around 46 kDa with W29C-Mal22 and all the derivatives modified at Q10C and R33C. For all these analogues, therefore, the toxin (molecular mass of 7 kDa) migrates with an apparent mass of approximately 46 kDa. No such detection was seen with other derivatives.

To establish whether the alpha -subunit is also present in the new 46-kDa band, we performed a similar blot experiment with an alpha -subunit-specific monoclonal antibody (33) (Fig. 4C). The control revealed an intense band migrating at the expected position of the free alpha -subunit (40 kDa). An additional band was seen around 46 kDa with the three derivatives modified at Q10C and R33C and with the longest derivative at W29C, confirming that, when these derivatives were present, the alpha -subunit migrated with a larger apparent molecular mass. In other words, these particular toxin derivatives comigrated with the alpha -subunit, a finding that strongly indicated their covalent association. We observed a similar though much weaker band with some other derivatives, in particular with K27C-Mal22, the two shorter W29C analogues, and the three K47C derivatives.

Coupling Yields at the alpha gamma Interface Binding Site-- To evaluate the coupling yield between toxin derivatives and the alpha -subunit at the alpha gamma interface, we monitored the band intensities at both 39 and 46 kDa by densitometry of the Coomassie Blue-stained gel for experiments where the reduced receptor and the derivatives were incubated for 15 and 90 min. The densitometry data must obviously be considered with caution, as they only reflect rough estimates of coupling yields whose determination was further complicated by the overlap of the intensity of the beta -subunit, which added to background errors. However, these coupling yields seem to be in good agreement with the sensitive alpha -subunit immunoblot detection (Fig. 4C). Though the novel band at 46 kDa was not detectable by immunoblot experiments for the two shorter derivatives at Lys27 (Fig. 4C, lanes 5 and 6), a small coupling yield (around 10%) was determined by gel densitometry (Fig. 5). We therefore considered this value as the threshold above which coupling was significant.


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 5.   Coupling yields of the various toxin derivatives to the alpha -subunit of the nAChR on the alpha gamma interface. The labeling yields were estimated by gel densitometry (DensyLab, Microvision Instruments, Evry, France) in each lane of Coomassie Blue-stained gels, between the alpha -subunit band and the 46-kDa band. Comparing the intensity of the unreacted alpha -subunit in each lane with respect to the uncoupled receptor lane gave rise to equivalent results. Due to a lack of precision of the method, related to high background and superimposition of the beta -subunit band with the (alpha  + toxin) band, only labeling yields higher than 10% were considered as representative. Two experiments were considered at different incubation times between the reduced receptor and the 15 toxin analogues: 15 min (gray) and 90 min (hatched) incubation. 10, 14, and 22 represent the Mal10, Mal14, and Mal22 reactive linkers on each derivative Q10C, K27C, W29C, R33C, and K47C. Error bars represent a 10% mean error evaluated after several intensity measurements of each 39- and 46-kDa band on each lane.

Irrespective of the position of the probe, no more than approximately half of the two alpha -subunits were labeled, showing that a single site was labeled under our experimental conditions, where the reducing agent was removed before reaction of the toxin (18, 21, 22, 39) (Fig. 5). Furthermore, it is known that low concentrations of bromoacetylcholine label the reduced receptor exclusively at the alpha gamma interface (22, 23). In agreement with the view that the same site was probed by our derivatives, we found that preincubation with a low concentration (10 µM) of bromoacetylcholine fully inhibited labeling with R33C-Mal22 (Fig. 4D). Therefore, our data support the view that the observed coupling occurs selectively on the reduced disulfide at the alpha gamma interface. The average 50% maximal coupling yield that was observed with respect to both alpha -subunits therefore corresponds to 100% labeling at the alpha gamma interface (Fig. 5).

Fig. 5 shows that coupling yields obtained with Q10C-Mal22, W29C-Mal22, and the three derivatives of R33C were approximately 100% after both 15- and 90-min incubations. This suggests that the maximal coupling was reached within 15 min, in good agreement with an affinity-labeling process (39). Fig. 5 also shows that each modified toxin position behaved in a unique manner. At position 33, quantitative coupling was observed irrespective of the size of the spacer. At position 10, a 70-80% coupling yield was seen with the two shorter linkers and quantitative coupling with the Mal22 arm. At position 29, the coupling yield was 30% and 45% with the Mal10 and Mal14 spacers, respectively, and coupling was complete with the Mal22 spacer. Finally, the longest probe at position 27 and the three probes at position 47 led to at most 20-30% coupling, whereas the two shorter arms at position 27 led to virtually no coupling.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We prepared 15 derivatives of a snake toxin, each of them possessing a single maleimido moiety. We used these derivatives to localize the toxin spatially relative to cysteines 192 and/or 193 of the reduced alpha -subunit of the nAChR. Two lines of evidence indicated that only cysteines at the alpha gamma interface of nAChR were labeled. First, previous data showed that, under the same experimental conditions as those used in this study, only half of the toxin binding sites were labeled by a small receptor antagonist (8, 22, 40, 41). Accordingly, we observed a maximal coupling yield of the alpha -subunits of approximately 50%. Second, data from several laboratories (11, 22-24) demonstrated that the labeled site is at the alpha gamma interface, this site being selectively discriminated by low concentrations of bromoacetylcholine (22, 41). In agreement with these findings, we observed that small amounts of the same reagent fully inhibit toxin labeling.

To interpret our coupling data in terms of relative positions between the two receptor cysteines and the toxin, a number of assumptions had to be made. First, because the two shorter spacers (Mal10 and Mal14) are highly rigid, the maleimides located at their tips were considered to describe a surface controlled by the movement of the spacers. We assumed that the movement of the reactive carbons of the maleimides encompassed the surfaces of two spheres with radii of 10 and 14 Å centered, respectively, on the alpha -carbon of the modified residue. Second, because we observed almost comparable full coupling with the two shorter arms, we assumed that at least one of the thiolates of cysteines 192 and 193 is present in a volume comprised between two spheres with radii of approximately 11.5 and 15.5 Å (the distance between the reactive carbon and thiols is assumed to be approximately 1.5 Å). We called these volumes the "reactive volumes." Third, bearing in mind the imprecision of the data shown in Fig. 5, we considered that the coupling yields with the two shorter arms at positions 10 correspond approximately to full coupling, like those at positions 33. Fourth, for partial but significant coupling, in the range of 30-50%, as observed with W29C derivatives, we considered that the reactive carbon was in proximity but not directly involved in the reactive volumes. Fifth, because the longer arm is highly flexible, we assumed it encompassed a large volume, which is difficult to predict, separated at most by 22 Å from the Calpha of the considered residue.

In addition to these assumptions, a number of elements had to be considered. First, the coupling yield is influenced by the distance that separates the thiols and the maleimides and by the accessibility of the sulfhydryl which, for example, could be favorably (or unfavorably) orientated for the attack of the thiolate perpendicularly to the plane of the maleimide ring. Second, at the molecular level, only one of the two cysteines can effectively react with the proposed maleimido group but, on average, a mixed population of labeled cysteines is likely to be generated, the relative proportion of labeled cysteines probably varying from one derivative to another. Bearing all these assumptions and considerations in mind, we interpreted our coupling data in terms of possible distances separating cysteines 192 and/or 193 from the alpha -carbon to which the reacting maleimido group was linked.

With the Q10C and R33C derivatives, the two short linkers led to virtually full coupling, so at least one of thiols 192 and 193 is likely to be at the intersection of the two reactive volumes centered on Calpha 10 and Calpha 33. The resulting volume adopted a "croissant-like" shape (partially visible in Fig. 6B) located in between the first and second loops almost perpendicularly to the plane of the large beta -sheet defined by the three toxin loops and orientated at nearly 45° from the axis of the central loop (Fig. 6A). K47C-Mal22 showed almost no coupling, suggesting that the corresponding Calpha is more than 23.5 Å from the reactive thiol(s). We therefore amputated the croissant-like area by about one fourth of its volume, in the region close to the second loop of the toxin. Interestingly, the reactive carbon of the W29C-Mal14 derivative, which showed no more than 50% coupling, brushed against the remaining volume. In Fig. 6 we colored violet the region of the remaining reactive volume, which is located 15.5 Å from the Calpha 29. In conclusion, the thiol(s) of Cys192 and/or Cys193 at the alpha gamma interface of the reduced Torpedo nAChR, is(are) most likely to belong to the remaining volume (colored yellow), in close proximity to the violet zone, which is framed by the three maleimides displayed by Q10C-Mal10, W29C-Mal14, and R33C-Mal10 (Fig. 6). Because binding of the receptor antagonists does not seem to be affected by reduction of the disulfide bond alpha (Cys192-Cys193) (16), we suggest that our data also reflect the positioning of the toxin when bound to native nAChR.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 6.   Putative position of the reactive thiol(s) of the reduced alpha (Cys192-Cys193) disulfide bond, on the alpha gamma interface, with respect to N. nigricollis alpha -neurotoxin. N. nigricollis alpha -neurotoxin skeleton is represented as an orange tube. The five modified positions have been visualized, i.e. 10, 27, 29, 33, and 47 with their corresponding native residue label. A high temperature molecular dynamics simulation (1000 K) of a dummy atom restrained by two constraints, i.e. to be located between 11.5 and 15.5 Å from the Calpha 10 and Calpha 33 (full coupling with the two shorter linkers for Q10C and R33C derivatives), engendered a croissant-like volume. A filter, suppressing the area located at less than 23.5 Å from Calpha 47 (no coupling with K47C-Mal22) restricted this volume to the depicted dots. Another filter allowed us to visualize the area located at 15.5 Å from Calpha 29 (partial labeling with W29C-Mal14) (violet dots). All together, Q10C-Mal10 (labeled Gln10), W29C-Mal14 (labeled Trp29), and R33C-Mal10 (labeled Arg33) were drawn pointing at the most probable area of localization of the reactive(s) thiolate(s) of Cys192 and/or Cys193. Because K27C and K47C derivatives did not lead to any coupling to the reduced receptor, the original lysinyl residues have been shown. A, view from the receptor face; B, view from the bottom of the toxin.

Considering the rather large distance that separates the thiol(s) occupying the identified region of the reduced receptor and the closest toxin residues, Gln10, Arg33, and Ile35, we suggest that the considered thiol(s) is(are) not fully hidden when the toxin is bound to its receptor. This situation could thus explain why the bound toxin does not fully protect labeling of the reduced receptor alpha -subunit with bromoacetylcholine (42) or N-ethylmaleimide.2 Probably, therefore, the reactive thiol(s) is (are) not in direct interaction with the toxin. Possibly also, the low coupling yields observed for the K27C and K47C derivatives (<30%) may be due to the flexibility and/or the accommodation of the molecules during the interaction between the receptor and toxin.

It was previously suggested that the positively charged quaternary ammonium ion of the antagonist MBTA is located at about 10 Å from the alpha (Cys192-Cys193) disulfide bond (8). Based on circumstantial evidence, it was also proposed that ammonium cations of small organic ligands may be mimicked by the positive charge of Arg33 of curarimimetic toxins (43, 44). Considering the present data, Arg33 is indeed the only positively charged toxin residue that is consistent with the proposed mimicry, the positive charges of the two other candidates (Lys27 and Lys47) being too remote from the disulfide bond.

How does our conclusion fit with previous experiments (13, 15, 45-47) designed to position a short or a long-chain toxin with respect to nAChR? An NMR study of a complex between the long-chain alpha -Bgtx and a dodecapeptide of the Torpedo receptor (alpha 185-196) indicated that the region alpha 186-190 is located between the first and the second loops of the toxin (46). Another NMR study of a complex between alpha -bungarotoxin and a library-derived peptide sharing some similarity with the receptor peptide alpha 187-199 showed that this 13-mer peptide also binds roughly in between the first and second toxin loops. Both studies clearly agree with our findings that the receptor region comprising alpha (Cys192-Cys193) is located in between the first and second loops of a snake toxin. In one study, the peptide residues that are homologous to cysteines 192 and 193 were too mobile to be located (46). In the other study (47), these residues do not fit in the reactive region, but are located much more to the back of the plane defined by the large beta -sheet of alpha -bungarotoxin. More precisely, the distance that separates the region colored violet (Fig. 6) from those peptide residues is approximately 15 Å. This situation might result from differential binding between short (this study) and long toxins (46, 47). Two lines of evidence support this view. First, a derivative of a long-chain toxin modified on the residue homologous to Lys27 with a mercurial compound similar in length to our Mal14 derivative, slightly coupled to the reduced cysteines of the alpha -subunits (45), in contrast to our own findings. Second, recent data have indicated that the binding topographies of short- and long-chain neurotoxins for Torpedo AChR are not strictly identical (48). It could also be argued that the small peptides used in NMR studies might behave differently when free or integrated in the whole receptor. More work is needed to clarify this question.

Recently, double mutant cycle analyses have shown that when another short toxin, NmmI, binds at the alpha gamma interface of the non-reduced mouse muscular receptor, Arg33 of the toxin is in proximity to alpha Val188 and alpha Tyr190 (13). This result fully agrees with our proposed location of the disulfide bond alpha (Cys192-Cys193) at the same interface (Fig. 6). In addition, it was observed that Arg33 is also in close proximity to Trp55 and Leu119 of the gamma -subunit of the muscular receptor (15). Assuming that the Torpedo and mouse receptors are comparable, our data combined with those of Osaka provide a molecular basis for the positioning of a short-chain toxin relative to residues of the alpha - and gamma -subunit at the alpha gamma interface.

It is currently assumed that the sequential homology of gamma Asp174 and delta Asp180 is associated with an identical position of the two residues in their respective sites (49). Thus, a site-directed labeling experiment has shown that delta Asp180 is located 1 nm from the reduced disulfide bond alpha (Cys192-Cys193) (38, 50). Furthermore, gamma Asp174 was recently located near Lys47 and Lys48 on the third loop of NmmI toxin (15). Interestingly, our model (Fig. 6) shows that the homologous Lys47 on N. nigricollis toxin alpha , and therefore the interacting gamma Asp174 (15), are over 10 Å from the disulfide bond at the alpha gamma interface. This evidence thus suggests that the binding sites at the alpha gamma and alpha delta interfaces are structurally distinct.

In conclusion, the data reported in this paper describe the respective spatial positioning of an element of the nAChR and a snake toxin, a potent receptor antagonist. Together with recent double mutant cycle analyses (15), it offers a suitable molecular basis for building up the remaining receptor elements that interact with the toxin.

    ACKNOWLEDGEMENT

We thank Dr. H. Virelizier for electrospray mass spectrometry measurements.

    FOOTNOTES

* This work was supported in part by the Association Française contre les Myopathies.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Recipient of a fellowship from the Direction de la Recherche et de la Technologie from the Direction Générale des Armées.

Recipient of a fellowship from the Ministère de la Recherche et de l'Enseignement Supérieure.

Dagger Dagger To whom correspondence should be addressed: Tel.: 33-1-69-08-52-25; Fax: 33-1-69-08-90-71; E-mail: pascal.kessler@cea.fr.

Published, JBC Papers in Press, May 11, 2000, DOI 10.1074/jbc.M002362200

2 P. Kessler, personal observation.

    ABBREVIATIONS

The abbreviations used are: nAChR, nicotinic acetylcholine receptor; Mal10, N,N'-(1,2-phenylene)dimaleimide; Mal14, N,N'-(1,4-phenylene)dimaleimide; Mal22, N,N'-bis(3-maleimidopropionyl)-2-hydroxy-1,3-propanediamine; DTT, dithiothreitol; HPLC, high performance liquid chromatography; Bgtx, bungarotoxin; PAGE, polyacrylamide gel electrophoresis; PVDF, polyvinylidene fluoride; Fmoc, N-(9-fluorenyl)methoxycarbonyl; MBTA, [4-(N-maleimido)benzyl]trimethylammonium iodide.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Pillet, L., Trémeau, O., Ducancel, F., Drevet, P., Zinn-Justin, S., Pinkasfeld, S., Boulain, J. C., and Ménez, A. (1993) J. Biol. Chem. 268, 909-916
2. Trémeau, O., Lemaire, C., Drevet, P., Pinkasfeld, S., Ducancel, F., Boulain, J. C., and Ménez, A. (1995) J. Biol. Chem. 270, 9362-9369
3. Oswald, R. E., and Changeux, J. P. (1982) FEBS Lett. 139, 225-229
4. Hervé, M., Pillet, L., Humbert, P., Trémeau, O., Ducancel, F., Hirth, C., and Ménez, A. (1992) Eur. J. Biochem. 208, 125-131
5. Utkin, Y. N., Krivoshein, A. V., Davydov, V. L., Kasheverov, I. E., Franke, P., Maslennikov, I. V., Arseniev, A. S., Hucho, F., and Tsetlin, V. I. (1998) Eur. J. Biochem. 253, 229-235
6. Arias, H. R. (1997) Brain Res. Rev. 25, 133-191
7. Middleton, R. E., and Cohen, J. B. (1991) Biochemistry 30, 6987-6997
8. Kao, P. N., Dwork, J. A., Kaldany, J. R. R., Wideman, S. J., Stein, S., and Karlin, A. (1984) J. Biol. Chem. 259, 11662-11665
9. Dennis, M., Giraudat, J., Kotzyba-Hibert, F., Goeldner, M., Hirth, C., Chang, J. Y., Lazure, C., Chrétien, M., and Changeux, J. P. (1988) Biochemistry 27, 2346-2357
10. Abramson, S. N., Li, Y., Culver, P., and Taylor, P. (1989) J. Biol. Chem. 264, 12666-12672
11. Pedersen, S. E., and Cohen, J. B. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2785-2789
12. Chiara, D. C., and Cohen, J. B. (1997) J. Biol. Chem. 272, 32940-32950
13. Ackermann, E. J., Ang, E. T. H., Kanter, J. R., Tsigelny, I., and Taylor, P. (1998) J. Biol. Chem. 273, 10958-10964
14. Osaka, H., Malany, S., Kanter, J. R., Sine, S. M., and Taylor, P. (1999) J. Biol. Chem. 274, 9581-9586
15. Osaka, H., Malany, S., Molles, B., Sine, S., and Taylor, P. (2000) J. Biol. Chem. 275, 5478-5484
16. Barrantes, F. J. (1980) Biochemistry 19, 2957-2965
17. Karlin, A., and Winnik, M. (1968) Proc. Natl. Acad. Sci. U. S. A. 60, 668-674
18. Karlin, A., and Cowburn, D. (1973) Proc. Natl. Acad. Sci. U. S. A. 70, 3636-3640
19. Silman, I., and Karlin, A. (1969) Science 164, 1420-1421
20. Karlin, A. (1977) Methods Enzymol. 46, 582-590
21. Wolosin, J. M., Lyddiatt, A., Dolly, J. O., and Barnard, E. (1980) Eur. J. Biochem. 109, 495-505
22. Walker, J. W., Richardson, C. A., and McNamee, M. G. (1984) Biochemistry 23, 2329-2338
23. Ratnam, M., Gullick, W., Spiess, J., Wan, K., Criado, M., and Lindstrom, J. (1986) Biochemistry 25, 4268-4275
24. Blount, P., and Merlie, J. (1989) Neuron 3, 349-357
25. Saitoh, T., Oswald, R., Wennogle, L. D., and Changeux, J. P. (1980) FEBS Lett. 116, 30-36
26. Neubig, R. R., Krodel, E. K., Boyd, N. D., and Cohen, J. B. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 690-694
27. Schmidt, J., and Raftery, M. A. (1973) Anal. Biochem. 52, 349-354
28. Mourier, G., Zinn-Justin, S., Trémeau, O., and Ménez, A. (1996) in Peptides (Epton, R. , and Ramage, R., eds) , pp. 659-660, Mayflower Scientific Ltd., Kingswinford, England
29. Ruoppolo, M., Moutiez, M., Mazzeo, M. F., Pucci, P., Ménez, A., Marino, G., and Quéméneur, E. (1998) Biochemistry 37, 16060-16068
30. Mourier, G., Servent, D., Zinn-Justin, S., and Ménez, A. (2000) Protein Eng. 13, 217-225
31. Cheng, Y. C., and Prusoff, W. H. (1973) Biochem. Pharmacol. 22, 3099-3108
32. Laemmli, U. K. (1970) Nature 227, 680-685
33. Tzartos, S. J., and Remoundos, M. S. (1992) Eur. J. Biochem. 207, 915-922
34. Ménez, A., Bouet, F., Tamiya, N., and Fromageot, P. (1976) Biochim. Biophys. Acta 453, 121-132
35. Ellman, G. L. (1959) Arch. Biochem. Biophys. 82, 70-77
36. Weber, M., and Changeux, J. P. (1974) Mol. Pharmacol. 10, 1-14
37. DiPaola, M., Czajkowski, C., and Karlin, A. (1989) J. Biol. Chem. 264, 15457-15463
38. Czajkowski, C., and Karlin, A. (1991) J. Biol. Chem. 266, 22603-22612
39. Karlin, A., McNamee, M., and Cowburn, D. (1976) Anal. Biochem. 76, 442-451
40. Damle, V. N., and Karlin, A. (1978) Biochemistry 17, 2039-2045
41. Damle, V., McLaughlin, M., and Karlin, A. (1978) Biochem. Biophys. Res. Commun. 84, 845-851
42. Dunn, S. M., Conti-Tronconi, B. M., and Raftery, M. A. (1993) Biochemistry 32, 8616-8621
43. Tsernoglou, D., and Petsko, G. A. (1976) FEBS Lett. 68, 1-4
44. Tsernoglou, D., Petsko, G. A., and Hudson, R. A. (1978) Mol. Pharmacol. 14, 710-716
45. Wohlfeil, E. R., and Hudson, R. A. (1991) Biochemistry 30, 7231-7241
46. Basus, V. J., Song, G., and Hawrot, E. (1993) Biochemistry 32, 12290-12298
47. Scherf, T., Balass, M., Fuchs, S., Katchalski-Katzir, E., and Anglister, J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6059-6064
48. Antil, S., Servent, D., and Ménez, A. (1999) J. Biol. Chem. 274, 34851-34858
49. Martin, M., Czajkowski, C., and Karlin, A. (1996) J. Biol. Chem. 271, 13497-13503
50. Czajkowski, C., and Karlin, A. (1995) J. Biol. Chem. 270, 3160-3164
51. Zinn-Justin, S., Roumestand, C., Gilquin, B., Bontems, F., Ménez, A., and Toma, F. (1992) Biochemistry 31, 11335-11347


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
F. Teixeira-Clerc, A. Menez, and P. Kessler
How Do Short Neurotoxins Bind to a Muscular-type Nicotinic Acetylcholine Receptor?
J. Biol. Chem., July 5, 2002; 277(28): 25741 - 25747.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Fruchart-Gaillard, B. Gilquin, S. Antil-Delbeke, N. Le Novere, T. Tamiya, P.-J. Corringer, J.-P. Changeux, A. Menez, and D. Servent
Experimentally based model of a complex between a snake toxin and the alpha 7 nicotinic receptor
PNAS, February 20, 2002; (2002) 42699899.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Zeng, L. Moise, M. A. Grant, and E. Hawrot
The Solution Structure of the Complex Formed between alpha -Bungarotoxin and an 18-mer Cognate Peptide Derived from the alpha 1 Subunit of the Nicotinic Acetylcholine Receptor from Torpedo californica
J. Biol. Chem., June 15, 2001; 276(25): 22930 - 22940.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Fruchart-Gaillard, B. Gilquin, S. Antil-Delbeke, N. Le Novere, T. Tamiya, P.-J. Corringer, J.-P. Changeux, A. Menez, and D. Servent
Experimentally based model of a complex between a snake toxin and the alpha 7 nicotinic receptor
PNAS, March 5, 2002; 99(5): 3216 - 3221.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/33/25608    most recent
M002362200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michalet, S.
Right arrow Articles by Kessler, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michalet, S.
Right arrow Articles by Kessler, P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement